Vantage logo

Boehringer splashes the cash in Nash

Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.

Vantage logo

Boehringer pushes pipeline progress

The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…